For the analyzed cohort, ctDNA analysis identified at least 1 of the 3 poor prognosis factors, circulating tumor fraction greater than  10%, TP53 mutation, or FGFR1 gain in 42.3% (131 of 310) patients (Figure 4C). The gene discussed is FGFR1; the disease is neoplasm.